Literature DB >> 9657950

Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica.

J T Roehrig1, R A Bolin, R G Kelly.   

Abstract

Although dengue (DEN) virus is the etiologic agent of dengue fever, the most prevalent vector-borne viral disease in the world, precise information on the antigenic structure of the dengue virion is limited. We have prepared a set of murine monoclonal antibodies (MAbs) specific for the envelope (E) glycoprotein of DEN 2 virus and used these antibodies in a comprehensive biological and biochemical analysis to identify 16 epitopes. Following domain nomenclature developed for the related flavivirus, tick-borne encephalitis, three functional domains were identified. Five epitopes associated with domain A were arranged in three spatially independent regions. These A-domain epitopes were destroyed by reduction, and antibodies reactive with these epitopes were able to block virus hemagglutination, neutralize virus infectivity, and block virus-mediated cell membrane fusion. Domain-A epitopes were present on the full-length E glycoprotein, a 45-kDa tryptic peptide representing its first 400 amino acids (aa) and a 22-kDa tryptic peptide representing at least aa 1-120. Four epitopes mapped into domain B, as determined by their partial resistance to reduction and the localization of these epitopes on a 9-kDa tryptic or chymotryptic peptide fragment (aa 300-400). One domain-B-reactive MAb was also capable of binding to a DEN 2 synthetic peptide corresponding to aa 333-351 of the E glycoprotein, confirming the location of this domain. Domain-B epitopes elicited MAbs that were potent neutralizers of virus infectivity and blocked hemagglutination, but they did not block virus-mediated cell-membrane fusion. Domains A and B were spatially associated. As with tick-borne encephalitis virus, determination of domain C was more problematic; however, at least four epitopes had biochemical characteristics consistent with C-domain epitopes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9657950     DOI: 10.1006/viro.1998.9200

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  140 in total

1.  Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells.

Authors:  W D Crill; J T Roehrig
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Structure of dengue virus: implications for flavivirus organization, maturation, and fusion.

Authors:  Richard J Kuhn; Wei Zhang; Michael G Rossmann; Sergei V Pletnev; Jeroen Corver; Edith Lenches; Christopher T Jones; Suchetana Mukhopadhyay; Paul R Chipman; Ellen G Strauss; Timothy S Baker; James H Strauss
Journal:  Cell       Date:  2002-03-08       Impact factor: 41.582

Review 3.  Dengue: defining protective versus pathologic immunity.

Authors:  Alan L Rothman
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

4.  Contribution of disulfide bridging to epitope expression of the dengue type 2 virus envelope glycoprotein.

Authors:  John T Roehrig; Katharine E Volpe; Jennifer Squires; Ann R Hunt; Brent S Davis; Gwong-Jen J Chang
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

5.  Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo.

Authors:  Katherine L Williams; Wahala M P B Wahala; Susana Orozco; Aravinda M de Silva; Eva Harris
Journal:  Virology       Date:  2012-04-25       Impact factor: 3.616

6.  Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles.

Authors:  Jiraphan Junjhon; Thomas J Edwards; Utaiwan Utaipat; Valorie D Bowman; Heather A Holdaway; Wei Zhang; Poonsook Keelapang; Chunya Puttikhunt; Rushika Perera; Paul R Chipman; Watchara Kasinrerk; Prida Malasit; Richard J Kuhn; Nopporn Sittisombut
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

7.  Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice.

Authors:  Juergen Zlatkovic; Karin Stiasny; Franz X Heinz
Journal:  J Virol       Date:  2010-12-08       Impact factor: 5.103

8.  Differentiation of West Nile and St. Louis encephalitis virus infections by use of noninfectious virus-like particles with reduced cross-reactivity.

Authors:  Jill A Roberson; Wayne D Crill; Gwong-Jen J Chang
Journal:  J Clin Microbiol       Date:  2007-08-22       Impact factor: 5.948

9.  Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.

Authors:  Ge Liu; Langzhou Song; David W C Beasley; Robert Putnak; Jason Parent; John Misczak; Hong Li; Lucia Reiserova; Xiangyu Liu; Haijun Tian; Wenzhe Liu; Darlene Labonte; Lihua Duan; Youngsun Kim; Linda Travalent; Devin Wigington; Bruce Weaver; Lynda Tussey
Journal:  Clin Vaccine Immunol       Date:  2015-03-11

10.  Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus.

Authors:  Gregory D Gromowski; Nicholas D Barrett; Alan D T Barrett
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.